Main content

Prostate Cancer Clinical Trials

Active Trials

Title: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
Description: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Investigators: CPMC Oncologists
Eligibility: Subjects who have histologic documentation of prostatic cancer
Status: Active and open to enrollment
Contact: Chrissy Raymundo, 415-600-3613, Email: RaymunCL@cpmcri.org about Study CALGB 90203

Title: A Randomized, Double-Blind, Phase III Trial Comparing Ipilimumab vs Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer (CRPC) That Have Received Prior Treatment with Docetaxel
Description: Study of Immunotherapy to Treat Advanced Prostate Cancer
Investigator: Ari Baron, MD
Eligibility: Male subjects, 18 years or older with advanced prostate cancer, at least 1 bone metastasis, testosterone < 50 ng/dl and who have had prior treatment with docetaxel
Status: Active and open to enrollment
Contact: Anna Ruiz, 415-600-3214, Email: RuizA@cpmcri.org about Study BMS CA 184-043

Title: A Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer
Description: Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Investigator: Ari Baron, MD
Eligibility: Male subjects, 18 years or older with metastatic prostate cancer and asymptomatic or minimally symptomatic
Status: Active and open to enrollment
Contact: Anna Ruiz, 415-600-3214, Email: RuizA@cpmcri.org about Study BMS CA 184-095

Title: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
Description: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Investigators: CPMC Oncologists
Eligibility: Subjects who have a histologically confirmed adenocarcinoma of the prostate diagnosed within the past 6 months
Status: Active and open to enrollment
Contact: Chrissy Raymundo, 415-600-3613, Email: RaymunCL@cpmcri.org about Study RTOG 0815

Title: A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer
Description: Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
Investigators: CPMC Oncologists
Eligibility: Subjects who have a diagnosis of adenocarcinoma of the prostate within the past 6 months
Status: Active and open to enrollment
Contact: Chrissy Raymundo, 415-600-3613, Email: RaymunCL@cpmcri.org about Study RTOG 0831

Title: A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Description: IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Investigator: Ari Baron, MD
Eligibility: Male subjects, 18 years or older who are currently receiving and must have had continuous therapy with GnRH monotherapy for at least 6 months before screening
Status: Coming Soon
Contact: Anna Ruiz, 415-600-3214, Email: RuizA@cpmcri.org about Study J&J 212082PCR2005

Title: Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 25 mg/m² and at 20 mg/m² in Combo with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer Not Previously Treated With Chemo
Description: Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (FIRSTANA)
Investigator: Ari Baron, MD
Eligibility: Male subjects, 18 years or older with progressive disease while receiving hormonal therapy or after surgical castration
Status: Coming Soon
Contact: Anna Ruiz, 415-600-3214, Email: RuizA@cpmcri.org about Study FIRSTANA

Title: Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Description: Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (PROSELICA)
Investigator: Ari Baron, MD
Eligibility: Male subjects, 18 years or older with a diagnosis of histologically or cytologically proven prostate adenocarcinoma, that is resistant to hormone therapy and previously treated with a docetaxel-containing regimen
Status: Coming Soon
Contact: Anna Ruiz, 415-600-3214, Email: RuizA@cpmcri.org about Study PROSELICA